GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Samsung Pharmaceutical Co., Ltd.
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 750
- sponsor
- Samsung Pharmaceutical Co., Ltd.
- conditions
- Moderate to Severe Alzheimer's Disease
- interventions
- DRUG: GV1001 Placebo; DRUG: GV1001 1.12mg
- start date
- 2027-07-01
- start date type
- ESTIMATED
- primary completion date
- 2028-01-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT05303701
- Published
- Mar 31, 2022
- Updated
- Jun 10, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT05303701
- Categories
- Moderate to Severe Alzheimer's Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials